SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-016721
Filing Date
2021-12-13
Accepted
2021-12-13 17:15:27
Documents
14
Period of Report
2021-12-09
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20211209x8k.htm   iXBRL 8-K 41014
2 EX-99.1 sgtx-20211209xex99d1.htm EX-99.1 11399
3 GRAPHIC sgtx-20211209xex99d1001.jpg GRAPHIC 5781
  Complete submission text file 0001558370-21-016721.txt   190492

Data Files

Seq Description Document Type Size
4 EX-101.SCH sgtx-20211209.xsd EX-101.SCH 3033
5 EX-101.LAB sgtx-20211209_lab.xml EX-101.LAB 16737
6 EX-101.PRE sgtx-20211209_pre.xml EX-101.PRE 10611
7 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20211209x8k_htm.xml XML 5053
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 211488853
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences